Optimal direct oral anticoagulant for upper gastrointestinal endoscopic submucosal dissection.

ABSTRACT:

Background

The patients taking direct oral anticoagulants (DOACs) are at high risk for developing ischemic stroke and delayed bleeding in upper gastrointestinal endoscopic submucosal dissection (ESD). We aimed to identify the optimal DOAC based on both adverse events in upper gastrointestinal ESD.

Methods

A retrospective population-based cohort study was conducted using the Diagnosis Procedure Combination database in Japan. We included patients on a DOAC undergoing upper gastrointestinal ESD between 2012 and 2021. The primary outcomes were ischemic stroke occurring after upper gastrointestinal ESD and delayed bleeding in gastroduodenal and esophageal ESD. Inverse probability weightings were applied to balance the four DOAC groups (dabigatran, rivaroxaban, apixaban, and edoxa

SUBMITTER: Ono Y 

PROVIDER: S-EPMC11717785 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature